Split-course chemoradiotherapy with S-1, a novel oral fluorouracil, and cisplatin for distant metastases of oesophageal cancer stage IVb
Journal Title: Journal of Cancer Research & Therapy - Year 2017, Vol 5, Issue 1
Abstract
Objectives: To evaluate the efficacy and safety of split-course chemoradiotherapy with S-1, a novel oral fluorouracil, together with cisplatin in patients with distant oesophageal cancer stage IVb metastasis. Methods: Forty-one patients with distant oesophageal cancer metastasis and performance status 0 or 1 received split-course chemoradiotherapy with S-1 and cisplatin. All 41 patients were reviewed retrospectively. Chemoradiotherapy comprised two courses of 30-Gy radiotherapy over three weeks plus daily oral S-1 (70mg/m2/day) for two weeks and a 24 h cisplatin infusion (70mg/m2) on Day 8, with a two week interval between the two courses. Results: The most frequent adverse events (AEs) were grade 3 and 4 neutropenia (29.2%), thrombocytopenia (9.8%), and anaemia (7.3%). Non-haematological AEs were generally mild. AEs in the initial course of chemoradiotherapy remitted during the second interval week. Overall, the complete response rate was 22.0% and endoscopic complete response rate for primary lesion was 65.9%. Thirty-one patients (75.6%) became asymptomatic and regained normal swallowing function. The overall median survival time was 12 months. Conclusion: This retrospective investigation showed that split-course chemoradiotherapy with S-1 and cisplatin had an encouraging safety profile together with good efficacy. Potentially, this regimen may become a standard for distant metastasis of oesophageal cancer stage IVb.
Authors and Affiliations
Hiroaki Iwase, Masaaki Shimada, Noboru Hirashima, Nobumitsu Ryuge, Momoko Goto, Takashi Kondo, Daiki Tanaka, Satoshi Unita, Eriko Kato
Keywords
Related Articles
- EP ID EP535755
- DOI 10.14312/2052-4994.2017-1
- Views 73
- Downloads 0
Plant-based omega-3 stearidonic acid enhances antitumor activity of doxorubicin in human prostate cancer cell lines
Doxorubicin (DOX) is a first choice cytostatic drug in treatment of many cancers but among its side effects is cardiac toxicity. Stearidonic omega-3 fatty acid (SDA) has cardiac protective qualities and, therefore, we in...
Development of a new formulation of interferons (HEBERPAG) for BCC treatment
Purpose: This work is aimed to show briefly, the clinical development of a new pharmaceutical formulation of interferons for the treatment of basal cell carcinoma. Methods: A rationale design of the combination of IFN-α2...
The first American cancer patient to receive dicycloplatin chemotherapy: A case report
Dicycloplatin (DCP), an effective platinum drug, was developed in China and approved by Chinese FDA in 2012. Its side effects are more bearable than those of cisplatin and carboplatin. The bladder cancer patient presente...
Changing clinical picture of endemic Burkitt’s lymphoma with improved diagnostic technology: A systematic review
We evaluated the changes in anatomical locations of endemic Burkitt’s lymphoma (eBL) by systematic review. We compared the reports before ultrasound became a routine investigation in Burkitt’s lymphoma (BL) diagnosis wit...
Evaluation of tissue 5´-Nucleotidase as tumor marker in breast and brain tumors using receiver operating characteristic curve
The pursuit of the ideal tumor marker has generated many testes for using in the diagnosis and management of cancer. Several of which are now widely available. The objective of the current study was to evaluate 5´-NT act...